Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

MiNK Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Investor Contact"
05/11/2023 8-K Quarterly results
Docs: "Press Release"
03/21/2023 8-K Quarterly results
Docs: "MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results NEW YORK, March 21, 2023 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022. “2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities," stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. "Our advancements have solidified MiNK's position as a leader in the iNKT cell the..."
11/03/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
01/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy